Contribution of Macropinocytosis in fibroblast activation and systemic sclerosis
Contribution of Macropinocytosis in fibroblast activation and systemic sclerosis
批准号:
10551908
负责人:
Konstantin Tsoyi
金额:
$17.6万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-02-01 至 2023-12-31
关键词:
AccelerationActinsAddressAmilorideAmino AcidsAnimal ModelApoptosisAttenuatedAutoimmune DiseasesAutomobile DrivingCause of DeathCell AgingCell SurvivalCellsCessation of lifeClathrinComplexComplicationDataDedicationsDermalDevelopmentDiseaseEffector CellEndocytosisEnvironmentExtracellular FluidExtracellular MatrixFatty AcidsFibroblastsFibrosisGene ExpressionGenetic TranscriptionGoalsHigh PrevalenceImipramineIn VitroInterstitial Lung DiseasesInvadedLaboratoriesLungLung fibrogenesisMediatingMolecularMorbidity - disease rateMusMyofibroblastNutrientOrganOrganellesPathogenesisPathogenicityPatientsPharmaceutical PreparationsPhenotypePhosphatidylinositolsPhosphotransferasesPinocytosisPlayPrevalenceProcessProductionProfibrotic signalProteinsPublishingPulmonary FibrosisResearchResistanceRespiratory FailureRheumatismRoleSclerodermaSignal PathwaySkinSmooth MuscleSystemic SclerodermaTGFB1 geneTechniquesTestingTherapeuticTherapeutic InterventionTuberous SclerosisUnited StatesUnited States Food and Drug AdministrationVacuolar Protein SortingVascular DiseasesViruscancer cellcell motilityclinical heterogeneityeffective therapyextracellularfeasibility testingfibrogenesisin vivoindium-bleomycininhibitorloss of functionmembermigrationmortalitypharmacologicpolypeptideprogramsresponseskin fibrosistherapeutic targettranscriptome sequencinguptake
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT
This R21 proposal describes a two-year research plan that will facilitate research program dedicated to
determining the role of macropinocytosis in systemic sclerosis (SSc, scleroderma) and SSc-associated interstitial
lung disease (ILD). SSc is an autoimmune disorder, which is manifested by skin fibrosis, vasculopathy and the
fibrosis of internal organs. The prevalence of SSc is estimated to range from 50 to 300 per million across the
world, with one of the highest prevalence rates observed in the United States at 240 per million. Because of its
clinical heterogeneity, SSc is a challenging disease to manage which results in the highest disease mortality
among the rheumatologic diseases. ILD is the most common lung complication of SSc and is associated with
increased mortality. ILD occurs in up to 80% of patients with SSc, with 25–30% developing a severe progressive
form of SSc-ILD leading to eventual respiratory failure and death. Little is known about the molecular
mechanisms involved in the pathogenesis of SSc and SSc-ILD. This project will focus on elucidating the key
roles of macropinocytosis in skin and lung fibrogenesis, as well as its therapeutic targeting. Macropinocytosis is
an actin-dependent but clathrin-independent endocytic process that mediates the nonselective internalization of
extracellular contents, such as proteins, cell debris, or viruses. Macropinocytosis has been shown to be involved
in cell survival, migration and invasion by providing nutrients (e.g., free amino acids and polypeptides) from
extracellular environment. However, its role in scleroderma and organ fibrogenesis is unknown. Our preliminary
findings suggest that inhibition of macropinocytosis attenuates dermal myofibroblast differentiation and
pulmonary fibrosis in mice. Furthermore, we found that vacuolar protein sorting 34 (Vps34), a sole member of
class III phosphoinositide-3-kinase (PI3K), is involved in macropinocytosis and fibroblast activation. Based on
published and our preliminary findings, we hypothesize that increased macropinocytosis promotes the
development of dermal and lung fibrosis in SSc. Thus, its inhibition exerts anti-fibrotic effects in the
animal model of skin fibrosis by reducing profibrotic responses in activated fibroblasts. We also
hypothesize that Vps34 is essential for macropinocytosis, which in turn confers to fibroblast activation.
We will test our hypotheses by addressing the following Specific Aims: Specific Aim #1: To demonstrate that
macropinocytosis inhibition attenuates dermal and lung fibrosis in mice by inhibiting fibroblast to myofibroblast
differentiation, ECM production, and migration. Specific Aim #2: To demonstrate that Vps34 is a key protein in
macropinosome formation and contributes to profibrotic responses of dermal and lung fibroblasts.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Contribution of Macropinocytosis in fibroblast activation and systemic sclerosis
-
批准号:10353766
-
项目类别:
-
资助金额:$21.12万
-
财政年份:2022
-
负责人:Konstantin Tsoyi
-
依托单位:
Antifibrotic effects of Syndecan-2 and CD148 in Rheumatoid Arthritis Interstitial Lung Disease
-
批准号:9892848
-
项目类别:
-
资助金额:$13.1万
-
财政年份:2020
-
负责人:Konstantin Tsoyi
-
依托单位:
Antifibrotic effects of Syndecan-2 and CD148 in Rheumatoid Arthritis Interstitial Lung Disease
-
批准号:10402333
-
项目类别:
-
资助金额:$13.1万
-
财政年份:2020
-
负责人:Konstantin Tsoyi
-
依托单位:
Antifibrotic effects of Syndecan-2 and CD148 in Rheumatoid Arthritis Interstitial Lung Disease
-
批准号:10630201
-
项目类别:
-
资助金额:$13.1万
-
财政年份:2020
-
负责人:Konstantin Tsoyi
-
依托单位:
海外基金